Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Ovarian Cancer | Research

MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer

Authors: Jian Lei, Jing-Ying Xu, Min Hu, San-Gang Wu, Juan Zhou

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Background

To illuminate the precise roles of MOB Kinase Activator 1 A (MOB1A) in the development of ovarian cancer (OC).

Methods

MOB1A expression and clinical data of OC were obtained from the public database on gene expression and proteomics. Meanwhile, verification of expression was carried out in Gene Expression Omnibus, the Human Protein Atlas, and OC cell lines. The prognosis of MOB1A was explored in the Kaplan-Meier plotter. RNA interference and lentivirus vectors were applied to construct knockdown and overexpressed cell models. Changes in the malignant behaviors of OC cells were detected by cholecystokinin octopeptide cell counting kit, wound healing, colony formation assay, transwell, flow cytometry assays, and in vivo experiments. Changes in proteins in the PI3K and autophagy-related makers were detected by western blot analysis.

Results

The expression of MOB1A was significantly upregulated and accompanied by an inferior survival rate in OC. Knockdown of MOB1A inhibited the proliferation, invasion, migration, and cell cycle of OC cells, whereas induced cell autophagy. MOB1A upregulation had the opposite effects. In addition, bioinformatics analysis and western blot experiments showed that MOB1A plays an important role in the PI3K/AKT/mTOR pathway.

Conclusions

Our findings indicated that MOB1A is highly expressed and related to poor prognosis in OC. MOB1A plays a role in promoting the malignant biological behavior of tumor cells through PI3K/AKT/mTOR signaling pathway.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Piver MS. Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncol (Williston Park). 2006;20(10):1156.
3.
Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19(5):961–8.PubMedCrossRef
4.
Bichsel SJ, Tamaskovic R, Stegert MR, Hemmings BA. Mechanism of activation of NDR (nuclear Dbf2-related) protein kinase by the hMOB1 protein. J Biol Chem. 2004;279(34):35228–35.PubMedCrossRef
5.
6.
7.
Kosaka Y, Mimori K, Tanaka F, Inoue H, Watanabe M, Mori M. Clinical significance of the loss of MATS1 mRNA expression in colorectal cancer. Int J Oncol. 2007;31(2):333–8.PubMed
8.
Lignitto L, Arcella A, Sepe M, Rinaldi L, Delle Donne R, Gallo A, et al. Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat Commun. 2013;4:1822.PubMedCrossRef
9.
Sugimachi K, Nishio M, Aishima S, Kuroda Y, Iguchi T, Komatsu H, et al. Altered expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma. Oncology. 2017;93(1):67–74.PubMedCrossRef
10.
Ando N, Tanaka K, Otsubo K, Toyokawa G, Ikematsu Y, Ide M, et al. Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer. Thorac Cancer. 2020;11(10):2830–9.PubMedPubMedCentralCrossRef
11.
Yang B, Li Y, Zhang R, Liu L, Miao H, Li Y, et al. MOB1A regulates glucose deprivation-induced autophagy via IL6-STAT3 pathway in gallbladder carcinoma. Am J Cancer Res. 2020;10(11):3896–910.PubMedPubMedCentral
12.
Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729–34.PubMedCrossRef
13.
Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013;22(4):641–64.PubMedCrossRef
14.
Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485(7396):55–61.PubMedPubMedCentralCrossRef
15.
Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: an overview. J Cell Physiol. 2018;233(5):3846–54.PubMedCrossRef
16.
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.PubMed
17.
Communal L, Roy N, Cahuzac M, Rahimi K, Kobel M, Provencher DM, et al. A keratin 7 and E-Cadherin signature is highly predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. Int J Mol Sci. 2021;22(10):5325.PubMedPubMedCentralCrossRef
18.
Enfield KSS, Marshall EA, Anderson C, Ng KW, Rahmati S, Xu Z, et al. Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. Nat Commun. 2019;10(1):5438.PubMedPubMedCentralCrossRef
19.
Liu Y, Li W, Luo J, Wu Y, Xu Y, Chen T, et al. Cysteine-Rich Intestinal protein 1 served as an epithelial ovarian Cancer marker via promoting Wnt/beta-Catenin-mediated EMT and Tumour Metastasis. Dis Markers. 2021;2021:3566749.PubMedPubMedCentralCrossRef
20.
Jin C, Yang M, Han X, Chu H, Zhang Y, Lu M, et al. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125. J Ovarian Res. 2019;12(1):114.PubMedPubMedCentralCrossRef
21.
Lou W, Ding B, Zhong G, Du C, Fan W, Fu P. Dysregulation of pseudogene/lncRNA-hsa-mir-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer. Aging. 2019;11(23):11416–39.PubMedPubMedCentralCrossRef
22.
Zhang M, Zhao L. CKAP2 promotes ovarian Cancer Proliferation and Tumorigenesis through the FAK-ERK pathway. DNA Cell Biol. 2017;36(11):983–90.PubMedCrossRef
23.
Wu S, Guo X, Zhou J, Zhu X, Chen H, Zhang K, et al. High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer. Aging. 2020;12(17):17079–98.PubMedPubMedCentralCrossRef
24.
Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13(8):877–83.PubMedPubMedCentralCrossRef
25.
26.
Quan M, Chen Z, Jiao F, Xiao X, Xia Q, Chen J, et al. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. J Exp Clin Cancer Res. 2020;39(1):13.PubMedPubMedCentralCrossRef
27.
28.
Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019;26(4):690–702.PubMedPubMedCentralCrossRef
29.
Pang Y, Si M, Sun B, Niu L, Xu X, Lu T, et al. DHA2, a synthesized derivative of bisbibenzyl, exerts antitumor activity against ovarian cancer through inhibition of XIAP and Akt/mTOR pathway. Food Chem Toxicol. 2014;69:163–74.PubMedCrossRef
30.
Li J, Cui G, Sun L, Wang SJ, Tian S, Guan Z, et al. ARHI overexpression induces epithelial ovarian cancer cell apoptosis and excessive autophagy. Int J Gynecol Cancer. 2014;24(3):437–43.PubMedCrossRef
31.
Jin Z, Zheng L, Xin X, Li Y, Hua T, Wu T, et al. Upregulation of forkhead box O3 transcription is involved in C2-ceramide induced apoptosis and autophagy in ovarian cancer cells in vitro. Mol Med Rep. 2014;10(6):3099–105.PubMedCrossRef
32.
Zi D, Zhou ZW, Yang YJ, Huang L, Zhou ZL, He SM, et al. Danusertib induces apoptosis, cell cycle arrest, and Autophagy but inhibits epithelial to mesenchymal transition involving PI3K/Akt/mTOR signaling pathway in human ovarian Cancer cells. Int J Mol Sci. 2015;16(11):27228–51.PubMedPubMedCentralCrossRef
33.
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.PubMedCrossRef
34.
Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–9.PubMedCrossRef
35.
Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26(12):2694–7.PubMedCrossRef
36.
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(Database issue):D991–5.PubMed
37.
Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318–30.CrossRef
38.
39.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.PubMedCrossRef
40.
Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227.PubMedPubMedCentralCrossRef
41.
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.PubMedPubMedCentralCrossRef
42.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77(21):e108–10.PubMedPubMedCentralCrossRef
43.
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.PubMedPubMedCentralCrossRef
44.
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.PubMedCrossRef
45.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef
Metadata
Title
MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer
Authors
Jian Lei
Jing-Ying Xu
Min Hu
San-Gang Wu
Juan Zhou
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00705-3

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

ABHD17C, a metabolic and immune-related gene signature, predicts prognosis and anti-PD1 therapy response in pancreatic cancer

Research

Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest

Research

A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer

Research

The potential immuno-stimulating effect of curcumin, piperine, and taurine combination in hepatocellular carcinoma; a pilot study

Research

Factors affecting local control of bone metastases from radioresistant tumors treated with palliative external beam radiotherapy

Research

A pan-cancer analysis for the oncogenic role of cyclin-dependent kinase inhibitor 1B in human cancers
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits